Trial will evaluate DF-006, a first-in-class ALPK1 agonist that stimulates local innate immunity in the liver
Guilford, CT & Shanghai, September 26, 2023–(BUSINESS WIRE)–Drug Farm, a clinical-stage biopharmaceutical company, today announced that it has studied the first patient with chronic hepatitis B in Part 3 of its Phase 1 clinical trial (ANZCTR Trial ID: ACTRN12621000592842). Medication. The trial is evaluating Drug Farm’s first-in-class ALPK1 agonist DF-006 as monotherapy and in combination with a standard-of-care nuclear